[Pharmacological adjuvants for surgical treatment of proliferative vitreoretinopathy].
Proliferative vitreoretinopathy (PVR) is the major cause of retinal detachment surgery failure. Many adjuvants were studied in vitro and on animals, some were studied on humans. Daunomycin seems to reduce PVR recidivism. 5-FU and steroids are nontoxic but their efficacy is not clear. Heparin reduced postoperative inflammation and seems to reduce PVR recidivism when associated with 5-FU. Associating heparin and steroids seems to reduce PVR in some groups of patients (aphakic, anterior PVR). Colchicine and retinoic acid per os are ineffective, silicone oil is effective as an internal tamponade but not as an adjuvant of PVR. Currently, no molecule has proven efficacy as an adjunctive treatment of PVR.
Scheer
S
S
CHNO des Quinze-Vingts, 28, rue de Charenton, 75012 Paris.
Morel
C
C
Touzeau
O
O
Sahel
J A
JA
Laroche
L
L
D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D003630:Daunorubicin / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D018630:Vitreoretinopathy, Proliferative / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery*
D005938:Glucocorticoids; D006493:Heparin; D003630:Daunorubicin